# A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT06296121** · PHASE3 · RECRUITING · sponsor: **Biocad** · enrollment: 252 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BCD-264
- **DRUG:** Darzalex

## Key facts

- **NCT ID:** NCT06296121
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-21
- **Primary completion:** 2025-01
- **Final completion:** 2026-07
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06296121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06296121, "A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06296121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*